Biotech stocks led gains on Monday, with sharp moves driven by a mix of financing news, regulatory milestones, and deal headlines. Entera Bio surged after announcing an oversubscribed private placement, while Gossamer Bio jumped on updates tied to its planned Seralutinib regulatory filing and corporate actions. Omeros also rallied after AstraZeneca reported a Phase 3 setback for its competing rare disease drug.
Key takeaways
- Entera Bio shares rose more than 90% after the company said an oversubscribed private placement is expected to raise about $275 million.
- Gossamer Bio advanced toward a September 2026 NDA for Seralutinib and regained worldwide rights from Chiesi, supporting a surge in the stock.
- Forte Biosciences jumped on an agreement to be acquired by argenx for $77 per share in cash.
- Omeros rallied after AstraZeneca’s Ultomiris failed to meet the primary endpoint in a Phase 3 trial, removing a near-term competitive overhang.
Financing and regulatory catalysts in the biotech space
Entera Bio was the standout gainer. The clinical-stage company said it entered into a securities purchase agreement for an oversubscribed private placement that is expected to generate approximately $275 million in gross proceeds, with closing expected on or about July 28, 2026. The funds would support its osteoporosis pipeline, led by EB613, described as the first oral anabolic bone-building tablet in development for osteoporosis.
Entera Bio also outlined its timeline for the next major clinical step: it plans to initiate a Phase 3 trial in late 2026, with topline results expected in the second half of 2028. The stock closed Monday at $3.92, up 91.22%.
Gossamer Bio moved higher as investors reacted to multiple company updates. The company said it expects to file a new drug application for Seralutinib to treat pulmonary arterial hypertension in September 2026, following a productive Pre-NDA Type B meeting with the FDA and receipt of the official meeting minutes.
Gossamer Bio also regained worldwide development and commercialization rights to Seralutinib from Chiesi. In addition, shareholders approved proposals tied to a previously announced convertible note exchange and authorized a reverse stock split. As of June 30, 2026, the company reported cash, cash equivalents, and marketable securities of approximately $57 million. Gossamer Bio closed at $0.19, up 46.62%.
Deal news and company actions drive additional upside
Forte Biosciences advanced sharply after agreeing to be acquired by argenx. Under the terms announced Monday, argenx will pay $77 per share in cash, implying a total equity value of roughly $2.2 billion. The acquisition is expected to close in Q3 2026.
Forte Biosciences is a clinical-stage biopharmaceutical company focused on FB102, a proprietary anti-CD122 monoclonal antibody with potential for broad autoimmune and autoimmune-related indications. The stock closed Monday at $76.50, up 39.65%.
Elsewhere in the group, Tevogen Bio shares jumped after the company moved forward with a broader healthcare services initiative. The company said the initiative is led on an interim basis by Vice President of Strategic Initiatives William Keane and includes evaluating acquisitions of a Management Services Organization and a Contract Research Organization. Management said the acquisitions, if completed, could generate approximately $100 million in combined annual revenue while supporting Tevogen’s goal of improving healthcare affordability and access. Tevogen’s Annual Meeting of Stockholders is scheduled for Monday, August 24, 2026. The shares closed Monday at $5.57, up 24.05%.
Pipeline momentum and competitive dynamics
First Tracks Biotherapeutics continued to draw momentum following its Nasdaq debut on April 20, 2026. The clinical-stage company is working on antibody therapeutics aimed at modulating immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in a Phase 1b trial for celiac disease and eosinophilic esophagitis; Rosnilimab, a pathogenic T cell depleter that completed a Phase 2b trial for rheumatoid arthritis; and ANB101, a BDCA2 modulator in a Phase 1a trial.
Shares closed Monday at $42.03, up 18.33%.
Omeros, meanwhile, gained on a risk-off shift in the competitive landscape for a rare disease indication. Shares rose more than 15% after AstraZeneca reported that its rare disease drug Ultomiris failed to meet the primary endpoint in a Phase 3 trial for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros markets YARTEMLEA, also indicated for HSCT-TMA, and analysts at H.C. Wainwright said the trial failure removes a key near-term competitive threat. Omeros closed Monday at $11.34, up 15.83%.
Investors are likely to watch the next inflection points across the group: Entera Bio’s progress toward late-2026 Phase 3 initiation, Gossamer Bio’s September 2026 NDA filing and related regulatory milestones, and merger timelines including argenx’s expected Q3 2026 close. For Omeros and its peers, competitive updates in HSCT-TMA development will remain a key driver, while upcoming biotech corporate events and stockholder meetings could add volatility in the near term.
